Amgen sues Samsung biotech unit over bone drug copies

Amgen (AMGN.O) has sued Samsung's biologics unit (207940.KS) in New Jersey federal court over its proposed biosimilar versions of Amgen's blockbuster bone drugs Prolia and Xgeva.